KMDA Stock Overview
Manufactures and sells plasma-derived protein therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Kamada Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪7.18 |
| 52 Week High | ₪9.16 |
| 52 Week Low | ₪4.74 |
| Beta | 0.21 |
| 1 Month Change | -11.25% |
| 3 Month Change | 22.32% |
| 1 Year Change | 28.21% |
| 3 Year Change | 21.69% |
| 5 Year Change | 33.96% |
| Change since IPO | -22.38% |
Recent News & Updates
Shareholder Returns
| KMDA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.1% | -1.2% | -4.1% |
| 1Y | 28.2% | -5.6% | 6.6% |
Return vs Industry: KMDA exceeded the US Biotechs industry which returned -5.6% over the past year.
Return vs Market: KMDA exceeded the US Market which returned 6.6% over the past year.
Price Volatility
| KMDA volatility | |
|---|---|
| KMDA Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: KMDA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KMDA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 420 | Amir London | www.kamada.com |
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers.
Kamada Ltd. Fundamentals Summary
| KMDA fundamental statistics | |
|---|---|
| Market cap | US$415.10m |
| Earnings (TTM) | US$14.46m |
| Revenue (TTM) | US$160.95m |
28.7x
P/E Ratio2.6x
P/S RatioIs KMDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KMDA income statement (TTM) | |
|---|---|
| Revenue | US$160.95m |
| Cost of Revenue | US$90.99m |
| Gross Profit | US$69.97m |
| Other Expenses | US$55.51m |
| Earnings | US$14.46m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 43.47% |
| Net Profit Margin | 8.99% |
| Debt/Equity Ratio | 0% |
How did KMDA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/14 21:50 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kamada Ltd. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | H.C. Wainwright & Co. |
| Anthony Petrone | Jefferies LLC |
| David Lewis | Morgan Stanley |